Here come the PD-1 agonists
Lilly shows that peresolimab is a goer, and others are not far behind; but what about the cancer risk?
Heightened US antitrust fears rattle biopharma
The FTC moves to block Amgen’s Horizon takeout, broadening its remit to curb anticompetitive moves that inflate drug prices.
Merck turns to Prometheus to bolster its post-Keytruda strategy
For $10.8bn the pharma giant gains a promising new mechanism, and adds immunology as a future investment area.
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
But Humira remains the one to beat.
